Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

John O. Mascarenhas, Salman Otoukesh, Terrence Bradley, Bart L. Scott, Habte A. Yimer, Souria Dougherty, Lixian Peng, Fei Huang, Ying Wan, Faye M. Feller, Vivian Rodolf, Judy Ho, Tymara Berry, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 998.

https://doi.org/10.1182/blood-2024-203800

Published: 2024

Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Blood (2024) 144 (Supplement 1): 655.

https://doi.org/10.1182/blood-2024-200312

Published: 2024

Journal Articles

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Mikkael A. Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts, Terrence Bradley, Justin Taylor, David Sallman, Zhuoer Xie, Eric Padron, Shelby Sullivan, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2024-203444

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Blood (2024) 144 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2024-197898

Published: 2024

Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Blood (2024) 144 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2024-200999

Published: 2024

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

Blood (2023) 142 (Supplement 1): 2913.

https://doi.org/10.1182/blood-2023-186620

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Anand Ashwin Patel, James J. Yoon, Hannah Johnston, Evan C. Chen, Madelyn Burkart, Timothy Seijung Oh, Sunil G. Iyer, Ellen Madarang, Iyana Gross, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Rory Michael Shallis, Guru Subramanian Guru Murthy, Vikas Gupta, Kristen M. Pettit, John Cursio, Olatoyosi Odenike

Blood (2022) 140 (Supplement 1): 6860–6862.

https://doi.org/10.1182/blood-2022-157603

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood (2022) 140 (Supplement 1): 9717–9720.

https://doi.org/10.1182/blood-2022-167122

Published: 2022

Journal Articles

MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis

Terrence Bradley, Andrew Kuykendall, Rami S. Komrokji, Tymara Berry, Souria Dougherty, Laurie Sherman, Lixian Peng, Fei Huang, Ying Wan, Faye Feller, John Mascarenhas

Blood (2022) 140 (Supplement 1): 3941–3942.

https://doi.org/10.1182/blood-2022-159614

Published: 2022

Journal Articles

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

Blood (2022) 140 (Supplement 1): 3306–3308.

https://doi.org/10.1182/blood-2022-170771

Published: 2022

Journal Articles

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Camille Abboud, Sr., Jan Maciej Zaucha, Scott R. Solomon, Terrence Bradley, Elie Mouhayar, Noemi Angelosanto, Hendrik Nogai, Renata Dudziak, Tomasz Rzymski, Peter Littlewood, Krzysztof Brzózka, Axel Glasmacher, Gautam Borthakur, Howard A. Burris, Sr., Ewa Lech Marańda

Blood (2022) 140 (Supplement 1): 6228–6229.

https://doi.org/10.1182/blood-2022-163150

Published: 2022

Journal Articles

Use of High Dose Cytarabine (HiDAC) for Post-Remission or Re-Induction Therapy Is Safe and Effective in Select Older AML Patients

Jillian Lykon, Ellen Madarang, Nina Nguyen, Wenhui Li, Sunil G. Iyer, Michele Stanchina, Terrence Bradley, Justin Taylor, Namrata Sonia Chandhok, Mikkael A. Sekeres, Justin Watts

Blood (2021) 138 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2021-153143

Published: 2021

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions

Ellen Madarang, Jillian Lykon, Wenhui Li, Sunil Iyer, Michele Stanchina, Nina Nguyen, Terrence Bradley, Mikkael A. Sekeres, Justin Taylor, Namrata Sonia Chandhok, Justin Watts

Blood (2021) 138 (Supplement 1): 1259.

https://doi.org/10.1182/blood-2021-151738

Published: 2021

Journal Articles

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Camille Abboud, Sr., Gautam Borthakur, Scott R. Solomon, Howard A. Burris, Sr., Terrence Bradley, JAN Maciej Zaucha, Sr., Ewa Lech-Marańda, Krzysztof Brzozka, Tomasz Rzymski, Peter Littlewood, Elie Mouhayar, Setareh Shamsili, Noemi Angelosanto

Blood (2021) 138 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2021-151030

Published: 2021

Journal Articles

Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14)

Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, Skye Montoya, Jumana Afaghani, Terrence Bradley, Francesco Maura, Dickran Kazandjian, Jennifer R Chapman, Ola Landgren, James E. Hoffman, Justin Taylor

Blood (2021) 138 (Supplement 1): 2270.

https://doi.org/10.1182/blood-2021-146925

Published: 2021

NARROW

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Use of High Dose Cytarabine (HiDAC) for Post-Remission or Re-Induction Therapy Is Safe and Effective in Select Older AML Patients

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only